{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:53:50Z","timestamp":1791071630582,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold>To identify and validate the efficacious monotherapy dosing regimen for topiramate in children aged 2 to &lt;10\u2003years with newly diagnosed epilepsy using pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) modeling and simulation bridging.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold>Several models were developed in pediatric and adult populations to relate steady\u2010state trough plasma concentrations (C<jats:sub><jats:sc>min<\/jats:sc><\/jats:sub>) of topiramate to the magnitude of clinical effect in monotherapy and adjunctive settings. These models were integrated to derive and support the monotherapy dosing regimen for pediatric patients.<\/jats:p><jats:p><jats:bold><jats:styled-content>Key Findings:<\/jats:styled-content>\u2002<\/jats:bold>A two\u2010compartmental population PK model with first\u2010order absorption described the time course of topiramate C<jats:sub><jats:sc>min<\/jats:sc><\/jats:sub>as a function of dosing regimen. Disposition of topiramate was related to age, body weight, and use of various concomitant antiepileptic drugs. The PK\u2013PD model for monotherapy indicated that the hazard of time to first seizure decreased with increasing C<jats:sub><jats:sc>min<\/jats:sc><\/jats:sub>and time since randomization. Higher baseline seizure frequency increased risk for seizures. Age did not significantly influence hazard of time to first seizure after randomization to monotherapy. For adjunctive therapy, the distribution of drug and placebo responses was not significantly different among age groups. Based on the available PK\u2013PD modeling data, the dosing regimen expected to achieve a 65\u201375% seizure freedom rate after 1\u2003year for pediatric patients age 2\u201310\u2003years is approximately 6\u20139\u2003mg\/kg per day.<\/jats:p><jats:p><jats:bold><jats:styled-content>Significance:<\/jats:styled-content>\u2002<\/jats:bold>This analysis indicated no difference in PK\u2013PD of topiramate between adult and pediatric patients. Effects of indication and body weight on PK were adequately integrated into the model, and monotherapy dosing regimens were identified for children 2\u201310 years of age.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02598.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T16:43:22Z","timestamp":1285778602000},"page":"1954-1962","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacokinetic\u2013pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to &lt;10\u2003years of age"],"prefix":"10.1111","volume":"51","author":[{"given":"Ihab G.","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Nandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Nye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ochalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00485.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1983.tb04896.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-3565(24)37274-X","article-title":"Pharmacokinetic\u2010pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats","volume":"284","author":"Della Paschoa OE","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04754.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000048200.12663.BC"},{"key":"e_1_2_8_8_1","unstructured":"GirgisIG NandyP NyeJS FordL WangS CoxE(2009)Pharmacokinetic\u2010pharmacodynamic assessment of topiramate adjunctive therapy in epilepsy. American Conference on Pharmacometrics Mashantucket CT U.S.A."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807303997"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200110601"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.01.006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005055"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.04.007"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822020-00007"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-007-0012-7"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061469"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070248"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.04.020"},{"key":"e_1_2_8_19_1","unstructured":"NandyP GirgisIG CoxE MouldDR NessS FordL(2010)Population pharmacokinetic modeling and simulation to support pediatric treatment of seizure with topiramate. To be submitted to Clinical Pharmacokinetics."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2542"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01584.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455005.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307380001501105"},{"key":"e_1_2_8_24_1","volume-title":"Prescribing information","author":"Topamax","year":"2009"},{"key":"e_1_2_8_25_1","volume-title":"Guidance for Industry, Exposure\u2010Response Relationships \u2013 Study Design, Data Analysis, and Regulatory Applications","author":"U.S. Food and Drug Administration","year":"2003"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02598.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02598.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T03:55:19Z","timestamp":1740542119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02598.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,29]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02598.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02598.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,29]]}}}